Reference no: EM133369190
Assignment:
Using these articles:
1. Boceprevir - George Njoroge, Chen, Neng-Yang, & Piwinski (2008)
2. Glivec - Capdeville, Buchdunger, Zimmermann, & Matter (2002), USFDA (2006), and Peng, Lloyd, & Schran (2005)
3. Brivaracetam - Klitgaard, et al. (2016) and Rogawski (2009)
4. Remdesivir - Warren, et al. (2016)and Eastman, et al. (2020)
Determine the following for each drug:
a. Interpret the data from the journals to determine whether each drug is in line with Lipinski's rule of five.
b. Analyze the journals to list the properties of each drug in the context of ADME/PK (e.g. solubility, permeability, plasma protein binding, metabolism, distribution, elimination, Cmax, half-life, etc.), and comment on any key structural modifications that were done to address ADME issues.
c. Why is remdesivir administered as a prodrug? If the data is available, what is the maximum concentration (Cmax) of the drug in plasma and/or the target tissue that is observed when an animal is administered an efficacious dose?
d. Comment on the relationship of the concentration of the drug at its target tissue (or plasma) to the in vitro potency of the drug.